<DOC>
	<DOCNO>NCT00707967</DOCNO>
	<brief_summary>This study ass safety immunogenicity GSK Biologicals ' candidate TB vaccine ( 692342 ) administer 0 , 1 month HIV-positive adult live Switzerland .</brief_summary>
	<brief_title>Safety Immunogenicity Candidate Tuberculosis ( TB ) Vaccine HIV-positive Adults .</brief_title>
	<detailed_description />
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects Investigator believe comply requirement protocol . A male female , include , 18 50 year age time first vaccination . Written inform consent obtain subject prior study procedure . Subjects must HIVpositive must : receive Highly Active Antiretroviral therapy minimum 12 consecutive month prior screen document suppressed HIV1 RNA level follow HAARTtreatment . protocol define CD4+ T cell count screen If subject female , must nonchildbearing potential , must practice adequate contraception 30 day prior vaccination , negative pregnancy test continue precaution 2 month completion vaccination . Clinically acceptable laboratory value prior randomisation determine Investigator . No evidence TB disease pulmonary pathology confirm chest Xray . No history extrapulmonary TB . No history chemotherapy TB . Any change antiretroviral drug regimen within 12 week prior screen . Use investigational nonregistered product ( drug vaccine ) study vaccine within 30 day precede first dose study vaccine , plan use study period . Administration register live vaccine foreseen study within 30 day precede first dose study vaccine administration register inactivated vaccine within 14 day precede first dose study vaccine . History previous administration experimental Mycobacterium tuberculosis vaccine . History previous exposure experimental product contain component experimental vaccine . Chronic administration immunosuppressive immunemodifying drug within six month prior first vaccine dose . Administration immunoglobulins , immunotherapy and/or blood product within three month precede first dose study vaccination , plan administration study period . Any condition illness ( acute , chronic history ) medication , opinion Investigator might interfere evaluation safety immunogenicity vaccine . Planned participation participation another experimental protocol study period . A family history congenital hereditary immunodeficiency . â€¢Any chronic drug therapy , HAART prophylaxis opportunistic HIVrelated infection continue study period . Vitamins and/or dietary supplement , birth control pill , antihistamine seasonal allergy SSRIs allow . Subjects take follow medication : systemic steroid , interleukin , systemic interferon systemic chemotherapy . History allergic reaction anaphylaxis vaccine . History allergic disease reaction likely exacerbate component vaccine . History chronic alcohol consumption and/or drug abuse Investigator 's opinion would put subject risk . Pregnant female , lactate female female planning become pregnant stop contraception .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Tuberculosis vaccine</keyword>
</DOC>